دورية أكاديمية
أعرض في EDS

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

التفاصيل البيبلوغرافية
العنوان: Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.
المؤلفون: Gough MJ; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Center, Portland, OR 97213, USA., Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD
المصدر: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2010 Oct; Vol. 33 (8), pp. 798-809.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9706083 Publication Model: Print Cited Medium: Internet ISSN: 1537-4513 (Electronic) Linking ISSN: 15249557 NLM ISO Abbreviation: J Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Hagerstown, MD : Lippincott-Raven, c1997-
مواضيع طبية MeSH: Immunotherapy*, Antibodies, Monoclonal/*administration & dosage , CD8-Positive T-Lymphocytes/*metabolism , Sarcoma/*immunology , Sarcoma/*therapy , Skin Neoplasms/*immunology , Skin Neoplasms/*therapy, Animals ; Antibodies, Monoclonal/pharmacology ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Chemotherapy, Adjuvant ; Cytotoxicity, Immunologic/drug effects ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Neoplasm Recurrence, Local/prevention & control ; Radiotherapy ; Receptors, Antigen, T-Cell/genetics ; Receptors, OX40/agonists ; Receptors, OX40/immunology ; Sarcoma/pathology ; Sarcoma/surgery ; Skin Neoplasms/pathology ; Skin Neoplasms/surgery
مستخلص: The tumor recurrence from residual local or micrometastatic disease remains a problem in cancer therapy. In patients with soft tissue sarcoma and the patients with inoperable nonsmall cell lung cancer, local recurrence is common and significant mortality is caused by the subsequent emergence of metastatic disease. Thus, although the aim of the primary therapy is curative, the outcome may be improved by additional targeting of residual microscopic disease. We display in a murine model that surgical removal of a large primary sarcoma results in local recurrence in approximately 50% of animals. Depletion of CD8 T cells results in local recurrence in 100% of animals, indicating that these cells are involved in the control of residual disease. We further show that systemic adjuvant administration of αOX40 at surgery eliminates local recurrences. In this model, αOX40 acts to directly enhance tumor antigen-specific CD8 T-cell proliferation in the lymph node draining the surgical site, and results in increased tumor antigen-specific cytotoxicity in vivo. These results are also corroborated in a murine model of hypofractionated radiation therapy of lung cancer. Administration of αOX40 in combination with radiation significantly extended the survival compared with either agent alone, and resulted in a significant proportion of long-term tumor-free survivors. We conclude that αOX40 increases tumor antigen-specific CD8 T-cell cytotoxic activity resulting in improved endogenous immune control of residual microscopic disease, and we propose that adjuvant αOX40 administration may be a valuable addition to surgical and radiation therapy for cancer.
References: Annu Rev Immunol. 1998;16:137-61. (PMID: 9597127)
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34. (PMID: 15701862)
Am J Surg. 1978 Mar;135(3):367-71. (PMID: 343622)
Cancer Res. 2005 Mar 1;65(5):1761-9. (PMID: 15753372)
J Exp Med. 2009 May 11;206(5):1103-16. (PMID: 19414558)
Cancer Sci. 2008 Feb;99(2):361-7. (PMID: 18201271)
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1235-41. (PMID: 15001268)
J Immunol. 2006 Oct 1;177(7):4464-72. (PMID: 16982882)
Curr Treat Options Oncol. 2006 Nov;7(6):456-63. (PMID: 17032558)
J Immunol. 2000 Sep 15;165(6):3043-50. (PMID: 10975814)
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):227-32. (PMID: 10924993)
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61. (PMID: 9636188)
Ann Surg Oncol. 2000 Apr;7(3):232-8. (PMID: 10791855)
Clin Cancer Res. 2007 Mar 1;13(5):1493-502. (PMID: 17332294)
Lancet. 1964 Jul 18;2(7351):117-20. (PMID: 14160543)
Proc Natl Acad Sci U S A. 1977 May;74(5):2121-5. (PMID: 194247)
Gut. 1999 Dec;45(6):856-63. (PMID: 10562584)
Cell Immunol. 2004 Feb;227(2):93-102. (PMID: 15135291)
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):829-37. (PMID: 18411002)
Anticancer Res. 2006 Sep-Oct;26(5A):3445-53. (PMID: 17094465)
Cell. 1994 Jan 14;76(1):17-27. (PMID: 8287475)
Arch Dermatol Res. 2003 Mar;294(12):563-6. (PMID: 12624783)
J Immunol. 2005 Sep 15;175(6):3534-41. (PMID: 16148096)
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):229-34. (PMID: 8083118)
Nature. 2001 Apr 26;410(6832):1107-11. (PMID: 11323675)
Arch Surg. 1992 Nov;127(11):1285-9. (PMID: 1444788)
Perspect Vasc Surg Endovasc Ther. 2006 Mar;18(1):55-62. (PMID: 16628336)
J Immunol. 2004 Mar 15;172(6):3580-9. (PMID: 15004159)
Eur J Immunol. 2007 Jan;37(1):157-66. (PMID: 17183611)
J Immunol. 1999 May 15;162(10):5838-45. (PMID: 10229818)
J Clin Oncol. 1999 Sep;17(9):2772-80. (PMID: 10561352)
Chest. 2005 Sep;128(3):1461-7. (PMID: 16162744)
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15074-9. (PMID: 10611340)
Breast Cancer Res Treat. 2001 May;67(1):71-80. (PMID: 11518468)
J Immunol. 1998 Dec 15;161(12):6510-7. (PMID: 9862675)
J Immunol. 2007 Dec 1;179(11):7244-53. (PMID: 18025166)
J Immunol. 1997 Oct 15;159(8):3838-48. (PMID: 9378971)
J Exp Med. 1984 May 1;159(5):1312-21. (PMID: 6232336)
J Immunol. 1999 Dec 15;163(12):6520-9. (PMID: 10586044)
Radiology. 1976 Jan;118(1):201-10. (PMID: 1105662)
J Immunol. 2000 Feb 15;164(4):2160-9. (PMID: 10657670)
J Immunol. 1994 May 1;152(9):4712-21. (PMID: 7512604)
J Immunol. 2001 Dec 15;167(12):6804-11. (PMID: 11739496)
J Immunol. 2009 Oct 15;183(8):4853-7. (PMID: 19786544)
Cancer Gene Ther. 2006 Sep;13(9):864-72. (PMID: 16710346)
Cancer Invest. 1999;17(1):56-72. (PMID: 10999050)
Blood. 2009 Jul 16;114(3):589-95. (PMID: 19349616)
Eur J Immunol. 2009 Aug;39(8):2184-94. (PMID: 19672905)
Cell Immunol. 2001 Apr 10;209(1):63-75. (PMID: 11414737)
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1439-45. (PMID: 15817348)
J Exp Med. 2008 Apr 14;205(4):825-39. (PMID: 18362171)
Am J Clin Oncol. 2007 Dec;30(6):637-44. (PMID: 18091059)
Cancer Res. 2008 Jul 1;68(13):5206-15. (PMID: 18593921)
J Immunol. 2000 Jan 1;164(1):107-12. (PMID: 10605000)
J Natl Cancer Inst. 1957 Jun;18(6):769-78. (PMID: 13502695)
Blood. 2005 Apr 1;105(7):2845-51. (PMID: 15591118)
معلومات مُعتمدة: R01 CA122701 United States CA NCI NIH HHS; CA122701 United States CA NCI NIH HHS; R01 CA102577-08 United States CA NCI NIH HHS; R01 CA102577 United States CA NCI NIH HHS; CA102577 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Receptors, Antigen, T-Cell)
0 (Receptors, OX40)
تواريخ الأحداث: Date Created: 20100916 Date Completed: 20110517 Latest Revision: 20211020
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3563298
DOI: 10.1097/CJI.0b013e3181ee7095
PMID: 20842057
قاعدة البيانات: MEDLINE
الوصف
تدمد:1537-4513
DOI:10.1097/CJI.0b013e3181ee7095